Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 1
Average round size
info
The average size of a deal this fund participated in
$2M
Portfolio companies 1
Lead investments 1
Exits 1
Key employees Soon

Areas of investment

  • Health Care
  • Biopharma
  • Biotechnology
  • Medical
Summary

The fund is generally included in less than 2 deals every year. Deals in the range of 1 - 5 millions dollars are the general things for fund. The important activity for fund was in 2017.

Among the various public portfolio startups of the fund, we may underline Adgero Biopharmaceuticals Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most successful fund investment fields, there are Biotechnology, Biopharma.

The usual cause for the fund is to invest in rounds with 1 partaker. Despite the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, startups are often financed by SternAegis Ventures. In the next rounds fund is usually obtained by SternAegis Ventures.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical:
Typical Co-investors
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Shanghai Fudan-Zhangjiang Bio-Pharmaceutical:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Blue Shield of California California, San Francisco, United States
BUILD Capital Partners Salt Lake City, United States, Utah
Gemini Investors Massachusetts, United States, Wellesley
Guangzhou Jinkong Fund China, Guangdong, Guangzhou
Huadan Angel China, Hangzhou, Zhejiang
Jiahesheng Maoyi China, Fujian, Zhangpu
Newton Fund California, San Francisco, United States
Peakequity Pennsylvania, Radnor, United States
Qingke Huacheng Investment China, Guangdong, Shenzhen
RECAPEX Stockholm, Stockholm County, Sweden
Red Hook Capital California, Sunnyvale, United States
Season Two Ventures Bengaluru, India, Karnataka
Shenzhen Lianrun Oriental Equity Investment Fund Management China, Guangdong, Shenzhen
Smarter Capital Australia, Saint Leonards, Victoria
Third Millennium Russia Fund Richmond, United States, Virginia
TIAN JIAN Beijing, Beijing, China
Traffix Canada, Milton, Ontario
Wildcat Venture Partners California, San Mateo, United States
Zesheng Ziben China, Guangdong, Tianjin

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Shanghai Fudan-Zhangjiang Bio-Pharmaceutical?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 1
Average round size 2M
Peak activity year 2017
Lead investments 1
Exits 1
Crunchbase icon

Content report

The following text will be sent to our editors: